IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor-induced inflammatory arthritis - PubMed
2 hours ago
- #Cancer Immunotherapy
- #Immunology
- #Inflammatory Arthritis
- IL-6 receptor blockade targets a pathogenic Treg subset in immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA).
- A unique Treg population (AtpTreg) co-expressing CD137 and IL-6R was identified through multi-omics analysis, showing reduced immunosuppression and high IL-17 production.
- AtpTreg frequency correlates with arthritis severity but is paradoxically linked to improved overall survival in patients.
- Anti-IL6R therapy reduces AtpTreg levels and improves arthritis outcomes without compromising anti-tumor immunity.